← back to search

Álvaro Lassaletta

Clinica Universidad de Navarra · ES
Area of research
Genetics · Neurology
Research interest
Research interests include Glioma Diagnosis and Treatment, Neuroblastoma Research and Treatments, Childhood Cancer Survivors' Quality of Life, and Acute Lymphoblastic Leukemia research.
h-index
40
citations
7,205
works
258
NIH funding
primary concept
Medicine
email

Recent publications

Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions.
2025cited by 9position: contributordoi
An innovative virtual fellowship leveraging global and regional mentorship to foster pediatric neuro-oncologists in low/middle-income countries
Neuro-Oncology Advances 2025cited by 1position: middledoi
Recommended phase 2 dose for abemaciclib in combination with irinotecan and temozolomide in pediatric and young adult patients with relapsed/refractory solid tumors: Results from JPCS study (Part A)
EJC Paediatric Oncology 2025cited by 1position: contributordoi
Supplementary Figure S1 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
2025cited by 0position: contributordoi
Supplementary Table S1 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
2025cited by 0position: contributordoi
Supplementary Table S2 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
2025cited by 0position: contributordoi
Supplementary Table S3 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
2025cited by 0position: contributordoi
Data from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
2025cited by 0position: contributordoi
Supplementary Data S1 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
2025cited by 0position: contributordoi
Supplementary Table S5 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
2025cited by 0position: contributordoi
Supplementary Table S4 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
2025cited by 0position: contributordoi
Superior outcome but high incidence of pseudoprogression and unfavorable neurocognitive outcome in children with embryonal tumor with multylayered rosettes treated with radiation and high-dose chemotherapy with tandem autologous stem cell rescue
EJC Paediatric Oncology 2025cited by 0position: contributordoi
Supplementary Figure S2 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
2025cited by 0position: contributordoi
Clinical and biological landscape of constitutional mismatch-repair deficiency syndrome: an International Replication Repair Deficiency Consortium cohort study
The Lancet Oncology 2024cited by 58position: middledoi
Safety, outcomes, and pharmacokinetics of isavuconazole as a treatment for invasive fungal diseases in pediatric patients: a non-comparative phase 2 trial
Antimicrobial Agents and Chemotherapy 2024cited by 19position: middledoi
Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Clinical Cancer Research 2024cited by 11position: middledoi
Chemotherapy in pediatric low-grade gliomas (PLGG).
2024cited by 7position: contributordoi
Long-term sequelae and quality of life after childhood-onset craniopharyngioma: Results of a Spanish multicenter study.
2024cited by 5position: contributordoi
Novel Fibroblast Growth Factor Receptor 3-Fatty Acid Synthase Gene Fusion in Recurrent Epithelioid Glioblastoma Linked to Aggressive Clinical Progression.
2024cited by 1position: contributordoi
Artificial intelligence chatbots: Are they a reliable source for patients and families in pediatric neuro-oncology?
2024cited by 0position: contributordoi
HOW A PEDIATRIC NEURO-ONCOLOGY UNIT WAS MANAGED IN MADRID DURING THE FIRST WAVE OF THE COVID-19 PANDEMIC
2024cited by 0position: contributordoi
METHOTREXATE-INDUCED STROKE LIKE NEUROTOXICITY: CASE REPORT, EIGHT YEARS OF EXPERIENCE AND LITERATURE REVIEW.
2024cited by 0position: contributordoi
ECLIM-SEHOP: how to develop a platform to conduct academic trials for childhood cancer.
2024cited by 0position: contributordoi
Palliative care for children with central nervous system tumors: results of a Spanish multicenter study.
2024cited by 0position: contributordoi
Long-term sequelae and quality of life after childhood-onset craniopharyngioma: results of a Spanish multicenter study.
2024cited by 0position: contributordoi
Phase II Trial of Dabrafenib Plus Trametinib in Relapsed/Refractory <i>BRAF</i> V600–Mutant Pediatric High-Grade Glioma
Journal of Clinical Oncology 2023cited by 63position: middledoi
Sustained Survival Benefit in Recurrent Medulloblastoma by a Metronomic Antiangiogenic Regimen
JAMA Oncology 2023cited by 43position: middledoi
Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS malignancies: Safety, efficacy, biomarker, and pharmacokinetics-CheckMate 908.
2023cited by 41position: contributordoi
Neurocognitive outcomes in pediatric brain tumors after treatment with proton versus photon radiation: a systematic review and meta-analysis
World Journal of Pediatrics 2023cited by 34position: firstdoi
Sustained Survival Benefit in Recurrent Medulloblastoma by a Metronomic Antiangiogenic Regimen: A Nonrandomized Controlled Trial.
2023cited by 31position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 25 papers (2020–2025)L. Moreno · Hospital Universitario Virgen Macarena5 papers (2020–2025)Jordan R. Hansford · Women's & Children's Health Research Institute4 papers (2019–2023)Uri Tabori · Occupational Cancer Research Centre4 papers (2019–2020)Felisa Vázquez-Gómez · 4 papers (2022–2024)Felipe A. Calvo · Clinica Universidad de Navarra3 papers (2023–2023)Pedro L. Valenzuela · Universidad de Alcalá3 papers (2020–2023)Juan Bergua · Hospital de Sant Pau3 papers (2019–2019)Derek S. Tsang · Toronto Western Hospital3 papers (2019–2020)Manuel Ramírez-Orellana · Universidad Politécnica Metropolitana de Hidalgo3 papers (2020–2020)Josep‐Maria Ribera · Hospital Municipal de Badalona3 papers (2019–2019)Miguel A. Sanz · Aurora Medical Center3 papers (2019–2019)Javier de la Serna · Empresarios Agrupados3 papers (2019–2019)Ibrahim Qaddoumi · Tennessee Oncology2 papers (2021–2021)Alejandro Santos‐Lozano · Universidad Europea Miguel de Cervantes2 papers (2020–2020)Michael D. Taylor · Norcliffe Foundation2 papers (2019–2019)Maitane Andion · Hospital Infantil Universitario Niño Jesús2 papers (2022–2024)Andres Morales La Madrid · Hospital Sant Joan de Déu Barcelona2 papers (2020–2021)Vicente Santa-Maria Lopez · Hospital Sant Joan de Déu Barcelona2 papers (2024–2024)Bob Löwenberg · Amsterdam University College2 papers (2019–2019)